• Scheduling operating rooms: Achievements, challenges and pitfalls

      Samudra, Michael; Van Riet, Carla; Demeulemeester, Erik; Cardoen, Brecht; Vansteenkiste, Nancy; Rademakers, Frank (Journal of Scheduling, 2016)
      In hospitals, the operating room (OR) is a particularly expensive facility and thus efficient scheduling is imperative. This can be greatly supported by using advanced methods that are discussed in the academic literature. In order to help researchers and practitioners to select new relevant articles, we classify the recent OR planning and scheduling literature into tables regarding patient type, used performance measures, decisions made, OR up- and downstream facilities, uncertainty, research methodology and testing phase. Based on these classifications, we identify trends and promising topics. Additionally, we recognize three common pitfalls that hamper the adoption of research results by stakeholders: the lack of a clear choice of authors on whether to target researchers (contributing advanced methods) or practitioners (providing managerial insights), the use of ill-fitted performance measures in models and the failure to understandably report on the hospital setting and method-related assumptions. We provide specific guidelines that help to avoid these pitfalls. First, we show how to build up an article based on the choice of the target group (i.e., researchers or practitioners). Making a clear distinction between target groups impacts the problem setting, the research task, the reported findings, and the conclusions. Second, we discuss points that need to be considered by researchers when deciding on the used performance measures. Third, we list the assumptions that need to be included in articles in order to enable readers to decide whether the presented research is relevant to them.
    • Sequencing surgical cases in a day-care environment: An exact branch-and-price approach

      Cardoen, Brecht; Demeulemeester, Erik; Beliën, Jeroen (Computers & Operations Research, 2009)
    • Shedding light on reimbursement policies of companion diagnostics in European countries

      Govaerts, Laurenz; Simoens, Steven; Van Dyck, Walter; Huys, Isabelle (Value in Health, 2020)
      Ensuring access to precision medicine has been an issue because in some European countries, desynchronized reimbursement decision-making occurs between the medicine and the companion diagnostic (CDx). This has resulted in cases in which precision medicine is reimbursed but not the CDx. In overcoming this issue, an alignment of the decision-making process for reimbursement between the 2 entities should be considered. As pharmaceutical reimbursement procedures are meticulously covered in the literature, we set out to systematically map in vitro diagnostic (IVD) reimbursement procedures and identify policies for aligning these procedures with the pharmaceutical reimbursement procedures.
    • Strategic groups in the biopharmaceutical industry: Implications for performance

      Erden, Zeynep; von Krogh, Georg; Nytorp, Cecilia; Hultberg, Marcus (Drug Discovery Today, 2009)
      The biopharmaceutical industry is characterized by intense competition, high uncertainty, and strong dependence on scientific knowledge. We show that in order to succeed in this industry, firms need to be positioned along three strategic dimensions: the level of inter-firm R&D partnering, the level of diversification, and the size of the firm. Prior research has revealed that a firm's membership in so-called ‘strategic groups’ impacts strongly on its performance. This study analyzes strategic groups in the biopharmaceutical industry along the strategic dimensions listed. The performance of the groups differs significantly. The best performing groups are the ones that consist of large firms with a high level of in-house diversification across therapeutic areas and the medium-sized firms that pursue partnership with other companies.
    • A systematic review of the value assessment frameworks used within health technology assessment of Omics technologies and their actual adoption from HTA agencies

      Hoxhaj, Ilda; Govaerts, Laurenz; Simoens, Steven; Van Dyck, Walter; Huys, Isabelle; Gutiérrez-Ibarluzea, Iñaki; Boccia, Stefania (International Journal of Environmental Research and Public Health, 2020)
      Background: Omics technologies, enabling the measurements of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics), are valuable tools for personalized decision-making. We aimed to identify the existing value assessment frameworks used by health technology assessment (HTA) doers for the evaluation of omics technologies through a systematic review. Methods: PubMed, Scopus, Embase and Web of Science databases were searched to retrieve potential eligible articles published until 31 May 2020 in English. Additionally, through a desk research in HTA agencies' repositories, we retrieved the published reports on the practical use of these frameworks. Results: Twenty-three articles were included in the systematic review. Twenty-two frameworks, which addressed genetic and/or genomic technologies, were described. Most of them derived from the ACCE framework and evaluated the domains of analytical validity, clinical validity and clinical utility. We retrieved forty-five reports, which mainly addressed the commercial transcriptomic prognostics and next generation sequencing, and evaluated clinical effectiveness, economic aspects, and description and technical characteristics. Conclusions: A value assessment framework for the HTA evaluation of omics technologies is not standardized and accepted, yet. Our work reports that the most evaluated domains are analytical validity, clinical validity and clinical utility and economic aspects.
    • The dilemma of being a physician-patient

      Otte, Andreas; Audenaert, Kurt; Otte, Karina; De Man, Stefanie; Dierckx, Rudi (Medical Science Monitor, 2003)
    • The future of M&A in the pharmaceutical industry: Promoting or stifling innovation?

      Van Dyck, Walter; Neels, Leo (Finance Monthly, 2014)
      In the research-intensive pharmaceutical industry, two rationales for M&A prevail. First, deals may be intended to provide access to target companies’ markets or innovative treatments R&D programs and, second, economies of scale could boost cost-efficiency. Both rationales lead to increased valuation of the merged company. The $119 billion takeover approach by Pfizer, the largest drug maker in the world, was resisted by AstraZeneca, another pharmaceutical giant and crown jewel of the UK-based life sciences industry at an offer representing a 45% premium over its share price before Pfizer made its move public. What went wrong and do we see a fundamental trend towards more or maybe different M&A activity in the pharmaceutical industry?
    • The impact of incorporating nurse-specific characteristics in a cyclical scheduling aproach

      Maenhout, Broos; Vanhoucke, Mario (Journal of the Operational Research Society, 2009)
    • The price of success? Pharmaceutical IP and global healthcare: a positive alliance

      Neels, Leo; Van Dyck, Walter (Pharma Times Magazine, 2016)
      Pharma has struggled with the dilemma of drug pricing and patent enforcement in developing countries for decades. In an ideal world, everyone has access to quality health services without financial hardship, but, in the real world, not every country has a strong, efficient and well-run health system. In the past, pharmaceutical companies have been named and shamed for focusing on the richer countries that can afford to pay the prices needed to recoup high R&D costs – but things may be changing.
    • The publishing and patenting strategies of successful university spinoffs in the biopharmaceutical industry

      Erden, Zeynep (Drug Discovery Today, 2017)
      Firms in the biopharmaceutical industry send signals to investors about the value of their knowledge by disclosing it in the form of patents and publications. In this way, they can gain reputation even before having products on the market. This paper compares the patenting and publishing activities of university spinoffs with other biopharmaceutical firms. The findings suggest that successful university spinoffs and successful other firms (not university spinoffs) tend to follow different knowledge disclosure strategies. Whereas successful university spinoffs tend to emphasize the scientific value of their knowledge and gain reputation through their high-quality publications, other successful firms tend to emphasize the commercial value of their knowledge and gain reputation through high-quality patents.
    • Unlocking the value of personalised healthcare in Europe — breast cancer stratification

      Van Dyck, Walter; Gassull, Daniel; Vértes, Gergely; Jain, Prateek; Palaniappan, Muhilan; Schulthess, Duane; Tambuyzer, Erik; Hudson, Richard; Moran, Nuala (Health Policy and Technology, 2012)
      Through stratification, this simulation shows that there is great potential to improve the efficiency of treating breast cancer. By segmenting the female population at the age of 50 based on family history and genetic testing, our model shows a reduction in costs of breast cancer treatments by 37% with no loss of efficacy accomplished primarily through a 60% drop in incidence of metastatic stages of the disease. These programmes are not inexpensive, and require substantial upfront investments of roughly 2 billion GBP and continued annual investments of several hundred million GBP. However, our simulations show a positive NPV and ROI in approximately year 7 of the programme.
    • Variability in hospital treatment costs: A time-driven activity-based costing approach for early-stage invasive breast cancer patients

      Roman, Erin; Cardoen, Brecht; Decloedt, Jan; Roodhooft, Filip (BMJ Open, 2020)
      Objectives: Using a standardised diagnostic and generic treatment path for breast cancer, and the molecular subtype perspective, we aim to measure the impact of several patient and disease characteristics on the overall treatment cost for patients. Additionally, we aim to generate insights into the drivers of cost variability within one medical domain. Design: setting and participants. We conducted a retrospective study at a breast clinic in Belgium. We used 14 anonymous patient files for conducting our analysis. Results: Significant cost variations within each molecular subtype and across molecular subtypes were found. For the luminal A classification, the cost differential amounts to roughly 166%, with the greatest treatment cost amounting to US$29 780 relative to US$11 208 for a patient requiring fewer medical activities. The major driver for these cost variations relates to disease characteristics. For the luminal B classification, a cost difference of roughly 242% exists due to both disease-related and patient-related factors. The average treatment cost for triple negative patients amounted to US$26 923, this is considered to be a more aggressive type of cancer. The overall cost for HER2-enriched is driven by the inclusion of Herceptin, thus this subtype is impacted by disease characteristics. Cost variability across molecular classifications is impacted by the severity of the disease, thus disease-related factors are the major drivers of cost. Conclusions: Given the cost challenge in healthcare, the need for greater cost transparency has become imperative. Through our analysis, we generate initial insights into the drivers of cost variability for breast cancer. We found evidence that disease characteristics such as severity and more aggressive cancer forms such as HER2-enriched and triple negative have a significant impact on treatment cost across the different subtypes. Similarly, patient factors such as age and presence of gene mutation contribute to differences in treatment cost variability within molecular subtypes.
    • Vooruitblik op Forumdag 2007: zorg neemt kijkje in de keuken van commerciële dienstverlening

      Dierick, Koenraad; Wijers, S. (Tijdschrift voor Verzorging en Beheer, 2007)